Healthcare data interoperability means sharing information smoothly across different healthcare systems. These include electronic health records (EHRs), lab information systems, pharmacy systems, and clinical trial databases. In pharma, it also means sharing clinical research, drug development data, and patient results with healthcare providers.
Interoperability is important because patients often get care from many providers like hospitals, clinics, pharmacies, and researchers. Without good data sharing, important patient information is stuck in separate places. This makes it harder for doctors to give correct diagnoses and personalized treatments.
Doctors need detailed patient records—medical history, medicines, allergies, and lab results—right away to make the best decisions. This is even more important now as healthcare focuses on patient needs and rewarding good outcomes rather than just services.
Even though there are clear benefits, many U.S. healthcare groups face big problems when trying to connect their data systems. These problems include:
Healthcare leaders and IT teams can try these steps to solve interoperability problems:
Artificial intelligence (AI) can go through large amounts of patient data. It finds patterns, predicts disease risks, and suggests treatment options. This helps doctors make better decisions and eases their workload.
Healthcare leaders say AI tools can save about 15% of doctors’ time by doing routine tasks like data entry, scheduling, and billing. This frees doctors to spend more time with patients, making care better and reducing stress.
Generative AI is expected to change clinical trials. It helps speed up trial information submissions and includes more diverse patients. It can gather and create trial data faster, helping develop new medicines sooner by working with healthcare data.
AI helps improve data cleaning, standardization, and real-time analysis. Cloud AI platforms support large-scale data integration, helping keep patient records accurate and up to date, even with complex and huge amounts of data.
Automation of data sharing between healthcare providers and drug companies improves communication and supports real-time data exchange. It also helps all parties share responsibility for patient results, creating a more connected care system.
Automation is also useful for administrative tasks like front-office phone work. Companies such as Simbo AI offer AI-powered phone systems that help medical offices and care providers improve patient access, cut down wait times, and manage appointment scheduling.
By handling common phone questions and directing calls well, these AI tools reduce the work on office staff. This improves patient experience and helps offices run more smoothly. These front-end tools work well with back-end data sharing efforts, keeping patient communication and scheduling consistent.
Improving data sharing between healthcare and pharmaceutical groups in the U.S. needs several efforts. These include using shared standards, updating IT systems, applying AI and automation, and working together with all groups involved.
Though the process is complex and costly, the gains in patient care, cost savings, and efficiency make it worth doing. Healthcare leaders and managers should focus on interoperability as a basic part of care. They should use phased and flexible approaches that fit their own needs.
Using standards like FHIR and HL7, building cloud data platforms, improving security, and using AI-driven automation will help healthcare groups offer more coordinated and efficient patient care.
With ongoing work on these challenges, the U.S. healthcare system can better connect healthcare providers and drug companies. This will help patient data move safely and usefully across care steps. In the end, it will support better medical decisions, faster development of treatments, and better health results for patients across the country.
SAS forecasts a steady transformation in healthcare and life sciences, emphasizing integration, modernization of technology, and increased patient engagement in care direction. There won’t be sudden upheavals, but focused efforts to create resilient organizations.
Healthcare organizations and pharma will implement targeted AI applications to personalize patient care and accelerate drug development. Governance from CIOs, CTOs, and regulators will shape the use of AI through company-specific playbooks.
Generative AI will facilitate high-quality information extraction in clinical trials, leading to faster submissions, innovation in therapy development, and greater inclusion of underserved populations in research.
The convergence of healthcare and pharma will become foundational by 2025, driven by shared data and insights. However, challenges around data interoperability will persist, necessitating secure data flow across systems.
Many healthcare technology infrastructures remain outdated and fragmented. Substantial financial investment is needed to modernize systems, ensuring that data integrity, security, and usability are prioritized.
Payers and public health will focus on better communication, enabled by AI-driven analytics and real-time data exchanges, leading to shared accountability and healthier populations.
Proposed regulations like the European Health Data Space will allow hospitals to securely exchange patient data across borders, leading to innovative health consumer apps that utilize wearable data and health histories.
Robust data management is imperative due to increasing data complexity and regulatory demands. Organizations will enhance practices through cloud-based AI platforms for improved productivity and patient-centric processes.
AI will automate repetitive tasks in clinical settings, thereby improving work life for clinicians. This will enable them to focus more on patient care rather than administrative duties.
Government health agencies will seek to innovate and modernize by learning from successful models and deploying universally applicable projects, aiming to better detect and respond to health threats.